Clinical research

Identification of pathogenic mutations for a Wolfram syndrome pedigree by whole exome sequencing and analysis of its clinical characteristics

  • Xiangyu MENG ,
  • Dandan YAN ,
  • Xianghui CHEN ,
  • Siyu LAI ,
  • Yun XU ,
  • Ruina GENG ,
  • Hong ZHANG ,
  • Rong ZHANG ,
  • Cheng HU ,
  • Jing YAN
Expand
  • 1.Department of Endocrinology, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, China
    2.Department of Endocrinology and Metabolism, Shanghai Sixth People′s Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai Clinical Centre for Diabetes; Shanghai Key Laboratory of Diabetes Mellitus; Shanghai Diabetes Institute, Shanghai 200233, China
YAN Jing, E-mail: jingyan_1216@vip.163.com.

Received date: 2023-02-17

  Accepted date: 2023-07-21

  Online published: 2023-07-28

Supported by

General Cultivation Project of Shanghai Sixth People′s Hospital, Shanghai Jiao Tong University School of Medicine(Ynms202109);Shanghai Research Center for Endocrine and Metabolic Diseases(2022ZZ01002)

Abstract

Objective ·To identify the causative gene and mutations and describe the clinical traits in a Chinese diabetes pedigree suspected of Wolfram syndrome. Methods ·A total of 12 subjects from one family were included. The proband was admitted to the Department of Endocrinology, The First Affiliated Hospital of Xinxiang Medical University, for the first time in May 2013. Then he visited the hospital for follow-up in July 2022 and in April 2023, respectively. The other members of this family included the proband′s sister, father, mother, paternal grandfather, paternal grandmother, uncle, aunt, as well as maternal grandfather, maternal grandmother, and two brothers of the proband′s mother. Clinical data of all subjects were collected. The whole exome sequencing was used to screen the pathogenic genes and mutation sites of six members of the family, and Sanger sequencing was used to verify the above results. Effects of the mutation of the pathogenic gene WFS1 in Wolfram syndrome on the function of the wolframin protein were evaluated by bioinformatics softwares, including CADD, DANN, MetaSVM, Polyphen-2, SIFT and M-CAP. The three-dimensional structures of wild-type and mutant wolframin proteins were constructed with Swiss-Model software, and visualized with PyMOL software. Cluster Omega software was used for evaluating species conservation of WFS1 gene mutation sites. JNetPRED software was used for online prediction of wolframin protein secondary structure. Results ·The proband and his sister both carried R558H and S411Cfs*131 mutations, two compound heterozygous mutations of the Wolfram syndrome pathogenic gene WFS1. The proband′s father and parental grandfather both carried the R558H mutation, while the proband′s mother and maternal grandfather both carried the S411Cfs*131 mutation. The R558H mutation was a rare missense mutation, and the S411Cfs*131 mutation was a novel frameshift mutation. Bioinformatics analysis softwares predicted that the R558H mutation located in the α-helical structure of the wolframin protein. This mutation was a damage mutation and the amino acid sequence of the mutation region was highly conservative among 12 species with varying degrees of evolution, including humans. Conclusion ·Two causative mutations of WFS1 gene are identified in a Chinese diabetes pedigree by whole exome sequencing. The study supplements the existing genotype and phenotype profiles of Wolfram syndrome, which can realize early diagnosis of diabetes pedigrees and help in performing timely follow-up of patients, so as to achieve early intervention and treatment of this disease.

Cite this article

Xiangyu MENG , Dandan YAN , Xianghui CHEN , Siyu LAI , Yun XU , Ruina GENG , Hong ZHANG , Rong ZHANG , Cheng HU , Jing YAN . Identification of pathogenic mutations for a Wolfram syndrome pedigree by whole exome sequencing and analysis of its clinical characteristics[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2023 , 43(7) : 898 -905 . DOI: 10.3969/j.issn.1674-8115.2023.07.012

References

1 JORDAN D M, DO R. Using full genomic information to predict disease: breaking down the barriers between complex and Mendelian diseases[J]. Annu Rev Genomics Hum Genet, 2018, 19: 289-301.
2 SULLIVAN J A, SCHOCH K, SPILLMANN R C, et al. Exome/genome sequencing in undiagnosed syndromes[J]. Annu Rev Med, 2023, 74: 489-502.
3 LORD J, MCMULLAN D J, EBERHARDT R Y, et al. Prenatal exome sequencing analysis in fetal structural anomalies detected by ultrasonography (PAGE): a cohort study[J]. Lancet, 2019, 393(10173): 747-757.
4 WRIGHT C F, FITZPATRICK D R, FIRTH H V. Paediatric genomics: diagnosing rare disease in children[J]. Nat Rev Genet, 2018, 19(5): 253-268.
5 JURGENS S J, CHOI S H, MORRILL V N, et al. Analysis of rare genetic variation underlying cardiometabolic diseases and traits among 200 000 individuals in the UK Biobank[J]. Nat Genet, 2022, 54(3): 240-250.
6 ZHAO J, ZHANG S Q, JIANG Y, et al. Mutation analysis of the WFS1 gene in a Chinese family with autosomal-dominant non-syndrome deafness[J]. Sci Rep, 2022, 12(1): 22180.
7 ZHANG H C, COLCLOUGH K, GLOYN A L, et al. Monogenic diabetes: a gateway to precision medicine in diabetes[J]. J Clin Invest, 2021, 131(3): e142244.
8 LI X H, QUICK C, ZHOU H F, et al. Powerful, scalable and resource-efficient meta-analysis of rare variant associations in large whole genome sequencing studies[J]. Nat Genet, 2023, 55(1): 154-164.
9 GIBBS R A. The human genome project changed everything[J]. Nat Rev Genet, 2020, 21(10): 575-576.
10 FLANNICK J, MERCADER J M, FUCHSBERGER C, et al. Exome sequencing of 20 791 cases of type 2 diabetes and 24 440 controls[J]. Nature, 2019, 570(7759): 71-76.
11 TANAKA D, NAGASHIMA K, SASAKI M, et al. Exome sequencing identifies a new candidate mutation for susceptibility to diabetes in a family with highly aggregated type 2 diabetes[J]. Mol Genet Metab, 2013, 109(1): 112-117.
12 PALLOTTA M T, TASCINI G, CRISPOLDI R, et al. Wolfram syndrome, a rare neurodegenerative disease: from pathogenesis to future treatment perspectives[J]. J Transl Med, 2019, 17(1): 238.
13 MORIKAWA S, URANO F. The role of ER stress in diabetes: exploring pathological mechanisms using Wolfram syndrome[J]. Int J Mol Sci, 2022, 24(1): 230.
14 CROUZIER L, DANESE A, YASUI Y, et al. Activation of the sigma-1 receptor chaperone alleviates symptoms of Wolfram syndrome in preclinical models[J]. Sci Transl Med, 2022, 14(631): eabh3763.
15 WANG L L, LIU H Y, ZHANG X F, et al. WFS1 functions in ER export of vesicular cargo proteins in pancreatic β-cells[J]. Nat Commun, 2021, 12(1): 6996.
16 CHEN Y, ZHANG M, ZHOU Y Y, et al. Case report: a novel mutation in WFS1 gene (c.1756G>A p.A586T) is responsible for early clinical features of cognitive impairment and recurrent ischemic stroke[J]. Front Genet, 2023, 14: 1072978.
17 KABANOVSKI A, DONALDSON L, MARGOLIN E. Neuro-ophthalmological manifestations of Wolfram syndrome: case series and review of the literature[J]. J Neurol Sci, 2022, 437: 120267.
18 SMITH C J, CROCK P A, KING B R, et al. Phenotype-genotype correlations in a series of wolfram syndrome families[J]. Diabetes Care, 2004, 27(8): 2003-2009.
19 COLOSIMO A, GUIDA V, RIGOLI L, et al. Molecular detection of novel WFS1 mutations in patients with Wolfram syndrome by a DHPLC-based assay[J]. Hum Mutat, 2003, 21(6): 622-629.
20 CANO A, ROUZIER C, MONNOT S, et al. Identification of novel mutations in WFS1 and genotype-phenotype correlation in Wolfram syndrome[J]. Am J Med Genet A, 2007, 143A(14): 1605-1612.
Outlines

/